organization · Reporting owner

Hatteras Venture Advisors IV SBIC, LLC

Disclosed activity across 2 companies

Tapewire entity: 166141
SEC CIK: 0001675236

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
G1 Therapeutics, Inc.GTHX · Entity 87413	10% owner	May 30, 2018	June 01, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

G1 Therapeutics, Inc.

Report date May 30, 2018 · Filed June 01, 2018

Jointly reported with Thorp Clay, Hatteras Venture Partners IV SBIC, LP, INGRAM ROBERT ALEXANDER, Crumpler John, LEE KENNETH B JR, Reed Douglas MD

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,279,421	Reported balance After 2018-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,237,711	Reported balance After 2018-05-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Filing footnotes · ownership attribution and instrument terms

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Clearside Biomedical, Inc.

Report date January 17, 2017 · Filed January 19, 2017

Jointly reported with Hatteras Venture Partners IV SBIC, LP, Crumpler John, INGRAM ROBERT ALEXANDER, LEE KENNETH B JR, Reed Douglas MD, Thorp Clay

Section 16 reporting ended · disclosed 2017-01-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,060,514	Last balance in matching sequence After 2017-01-19 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2017-01-17 · Sale · Disposed 9,806 · Balance 2,080,364 F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 2 · 2017-01-18 · Sale · Disposed 12,258 · Balance 2,068,106 F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 3 · 2017-01-19 · Sale · Disposed 7,592 · Balance 2,060,514 F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 30, 2018 Filed Jun 1, 2018 18:22 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	41,710	$48.00	$2,002,080.00	Disclosure SEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,237,711 F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4 · ownership.nature: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV. Read SEC document
May 30, 2018 Filed Jun 1, 2018 18:22 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	758,290	$48.00	$36,397,920.00	Disclosure SEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,279,421 F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2 · ownership.nature: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. Read SEC document
May 23, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	26	$50.50	$1,313.00	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 8 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,037,711 F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV. F13 · ownership.nature: Following the reported transaction, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document
May 23, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	474	$50.50	$23,937.00	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 7 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,037,737 F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC. F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV. Read SEC document
May 22, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	308	$50.69	$15,611.01	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 6 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,038,211 F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV. F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document
May 22, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	5,592	$50.86	$284,405.21	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 5 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,038,519 F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC. F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV. Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	26	$52.13	$1,355.38	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 4 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,111 F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV. F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	474	$52.13	$24,709.62	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,137 F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC. F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV. Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	1,595	$51.06	$81,438.95	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,044,611 F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC. Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	SaleCommon Stock	29,005	$51.16	$1,483,907.40	Disclosure SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,046,206 F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Following the reported transaction, 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. Read SEC document
November 30, 2017 Filed Dec 4, 2017 17:01 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	OtherCommon Stock	995	$0.00	$0.00	Disclosure SEC source: 0001209191-17-063608 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,075,211 F5 · price: In-kind distribution from L2 Ventures, LLC to its members, including Hatteras Venture Advisors V, LLC, without consideration. F2 · ownership.nature: 3,861,797 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F6 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. Read SEC document
November 30, 2017 Filed Dec 4, 2017 17:01 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	OtherCommon Stock	99,513	$0.00	$0.00	Disclosure SEC source: 0001209191-17-063608 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner Crumpler John · CIK 0001674107 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,074,216 F1 · price: In-kind distribution from L2 Ventures, LLC to its members, without consideration. F2 · ownership.nature: 3,861,797 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: Following a distribution in-kind to its members, none of the reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities previously held by L2 Ventures were indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionSeries C Preferred Stock · Derivative	1,009,693	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 8 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 336,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F9 · ownership.nature: Includes shares of Series C Preferred Stock convertible into 294,493 shares of the Issuer's common stock held by HVP IV and shares of Series C Preferred Stock convertible into 42,070 shares of the Issuer's common stock held by L2 Ventures, LLC. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionSeries B Preferred Stock · Derivative	2,584,959	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 7 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 861,651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F8 · ownership.nature: Includes shares of Series B Preferred Stock convertible into 804,208 shares of the Issuer's common stock held by HVP IV and shares of Series B Preferred Stock convertible into 57,443 shares of the Issuer's common stock held by L2 Ventures, LLC. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionSeries A Preferred Stock · Derivative	6,568,527	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 6 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,189,508 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3 · ownership.nature: The reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F7 · ownership.nature: Includes shares of Series A Preferred Stock convertible into 1,990,276 shares of the Issuer's common stock held by HVP IV and shares of Series A Preferred Stock convertible into 199,232 shares of the Issuer's common stock held by Hatteras NC. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionSeries 1 Preferred Stock · Derivative	1,318,681	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 5 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 439,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	PurchaseCommon Stock	133,333	$15.00	$1,999,995.00	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 4 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners IV SBIC, LP Disclosed balance after: 3,861,797 F5 · price: Reflects shares Hatteras Venture Partners IV SBIC, LP purchased in the initial public offering at the initial public offering price of $15.00 per share. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionCommon Stock	99,513	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 3 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By L2 Ventures, LLC Disclosed balance after: 99,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionCommon Stock	212,419	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 2 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras NC Fund, LP Disclosed balance after: 212,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F3 · ownership.nature: The reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC	G1 Therapeutics, Inc. GTHX · Entity 87413	ConversionCommon Stock	3,728,464	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 1 Thorp Clay · CIK 0001592380 · 10% owner Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner Crumpler John · CIK 0001674107 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners IV SBIC, LP Disclosed balance after: 3,728,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
January 19, 2017 Filed Jan 19, 2017 19:31 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	SaleCommon Stock	7,592	$8.22	$62,406.24	Disclosure SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 3 Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,060,514 F4 · price: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
January 18, 2017 Filed Jan 19, 2017 19:31 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	SaleCommon Stock	12,258	$8.64	$105,909.12	Disclosure SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 2 Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,068,106 F3 · price: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
January 17, 2017 Filed Jan 19, 2017 19:31 UTC	Clearside Biomedical, Inc. CLSD · Entity 82875	SaleCommon Stock	9,806	$8.92	$87,469.52	Disclosure SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 1 Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,080,364 F1 · price: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.